ACM
DCOY

Altium Capital Management’s Decoy Therapeutics DCOY Stock Holding History

Altium Capital Management’s Portfolio DCOY Stock Details DCOY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-35
Closed -$1.85M – 150
2021
Q1 		$1.85M Buy
+35
New +$2.01M 0.51% 86

Other funds holding DCOY

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Altium Capital Management's DCOY Position: Q2 2021 in Review

Altium Capital Management sold out of Decoy Therapeutics (DCOY) in Q2 2021, closing a stake of 35 shares — an estimated $1.85M sold.

Altium Capital Management first reported a position in DCOY in Q1 2021 and held it in 1 quarter. The position peaked at $1.85M in Q1 2021. 27 funds tracked by Wall St. Rank hold DCOY as of Q2 2021.

  • Altium Capital Management reported no remaining Decoy Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Altium Capital Management sold 35 Decoy Therapeutics shares in Q2 2021, an estimated $1.85M.
  • Altium Capital Management first reported a position in Decoy Therapeutics in Q1 2021 and held it in 1 quarter.
  • Altium Capital Management's Decoy Therapeutics position peaked at $1.85M in Q1 2021.
  • 27 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q2 2021.

Based on Altium Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.